- Research works
- 80 ▲ 56% vs 2013–17
- Citations
- 1.3k 16.2 per fractional work
- Top-10% rate
- 12.4% record average 16.5%
- Open access
- 46% world 28%
Not ranked overall: Helix Biomedix (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Chemistry, 4.5×. Every wedge is a field page.
- Chemistry 4.5×
- Immunology and Microbiology 3.1×
- Medicine 3.0×
- Biochemistry, Genetics and Molecular Biology 2.4×
- Economics, Econometrics and Finance 1.5×
- Computer Science 0.9×
- Health Professions 0.8×
- Physics and Astronomy 0.5×
- Materials Science 0.4×
- Business, Management and Accounting 0.3×
- Agricultural and Biological Sciences 0.2×
- Engineering 0.1×
Who are the top researchers at Helix Biomedix (United States)?
Ranked on the composite score, Gary A. Pestano, Joanna Roder and Julia Grigorieva lead among researchers whose main affiliation is Helix Biomedix (United States).
- 1 Gary A. Pestano United States · #1,437,636 worldwide 1 citations · 16 works
- 2 Joanna Roder United States · #1,484,415 worldwide 9 citations · 15 works
- 3 Julia Grigorieva United States · #1,562,182 worldwide 20 citations · 15 works
Which keywords describe research at Helix Biomedix (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Targeted Therapy, Cancer Genomics, Mutational Signatures, Clinical Trials, Resistance Mechanisms, Chemotherapy, Treatment Guidelines and ALK Inhibitors.
- Normalization
- Genomics
- Therapeutic Agents
- Immune Modulation
- Gene Expression
- Immunotherapy
- Tumor Staging
- Prognostic Factors
- Protein Identification
- Lung Cancer
- Data Analysis
- Feature Extraction
- Biomarkers
- Tumor Microenvironment
- Precision Medicine
- Quantitative Analysis
- ALK Inhibitors
- Chemotherapy
- Clinical Trials
- Cancer Genomics
- Targeted Therapy
- Mutational Signatures
- Resistance Mechanisms
- Treatment Guidelines
- EGFR Mutations
- Mass Spectrometry
- Machine Learning
- Proteomics
- Medical Imaging
- Radiomics
- Innate Immunity
- Phosphoproteomics
- CT Screening
- Radiotherapy
- Immune Checkpoint Blockade
- PD-1 and PD-L1
- Host Defense
- Antimicrobial Peptides
- Metastasis
- NMR Spectroscopy
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Targeted Therapy20▲ 113×3 topics
- Cancer Genomics10▲ 232×1 topic
- Mutational Signatures10▲ 232×1 topic
- Clinical Trials10▲ 19×4 topics
- Resistance Mechanisms8▲ 132×2 topics
- Chemotherapy8▲ 14×10 topics
- Treatment Guidelines8▲ 44×2 topics
- ALK Inhibitors8▲ 169×1 topic
- EGFR Mutations8▲ 169×1 topic
- Quantitative Analysis7▲ 55×2 topics
- Mass Spectrometry7▲ 41×4 topics
- Precision Medicine7▲ 28×4 topics
- Machine Learning6▲ 3.2×6 topics
- Tumor Microenvironment5▲ 19×6 topics
- Proteomics5▲ 51×2 topics
- Biomarkers4▲ 8.6×6 topics
- Medical Imaging4▲ 19×2 topics
- Feature Extraction4▲ 18×1 topic
- Radiomics4▲ 77×1 topic
- Data Analysis4▲ 15×3 topics
- Innate Immunity4▲ 13×3 topics
- Lung Cancer3▲ 26×2 topics
- Phosphoproteomics3▲ 175×1 topic
- Protein Identification3▲ 175×1 topic
- CT Screening3▲ 73×1 topic
- Prognostic Factors3▲ 9.0×6 topics
- Radiotherapy3▲ 11×3 topics
- Tumor Staging3▲ 46×1 topic
- Immune Checkpoint Blockade3▲ 71×1 topic
- Immunotherapy3▲ 6.2×4 topics
- PD-1 and PD-L13▲ 71×1 topic
- Gene Expression3▲ 6.3×5 topics
- Host Defense3▲ 59×2 topics
- Immune Modulation3▲ 28×2 topics
- Antimicrobial Peptides3▲ 77×1 topic
- Therapeutic Agents3▲ 127×1 topic
- Metastasis3▲ 9.5×4 topics
- Genomics2▲ 8.6×4 topics
- NMR Spectroscopy2▲ 18×2 topics
- Normalization2▲ 34×2 topics
Which research topics does Helix Biomedix (United States) publish most on?
By volume in 2022–2025: Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics and Radiomics and Machine Learning in Medical Imaging.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 3 Cancer Genomics and Diagnostics Cancer Research 1 works
- 4 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 1 works
- 5 Advanced Proteomics Techniques and Applications Spectroscopy 1 works
- 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
- 7 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works
- 8 Colorectal Cancer Screening and Detection Oncology 0 works
- 9 Healthcare Regulation Health Information Management 0 works
- 10 Metabolomics and Mass Spectrometry Studies Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Helix Biomedix (United States)'s research output changed?
Output in 2018–2022 was 56% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Bothell
- University of Washington Bothell
- Modern Electron (United States)
- Radar (United States)
- Seagen (United States)
- EKOS Corporation
- Epoch Biosciences (United States)
- OncoGenex Pharmaceuticals (United States)
- Sonic Concepts (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.